Haupt Pharma has successfully passed FDA inspections at four sites in Germany during the first half of 2012. The Haupt Pharma Group now has six facilities approved to manufacture drugs for the U.S. market. The company provides development and manufacturing services for both conventional drugs and various specialty products, including cytotoxics, hormones, betalactam antibiotics, and narcotics.
“These successful audits help the group to come much closer to its strategic goal of further expanding its presence in the U.S. market,” said Dr. Karl Heinz Brücher, chief operating officer of Haupt Pharma AG. “This result is an extremely positive signal to our customers and the market as it reflects both the exceptional performance and the high level of quality of our sites.”